Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker fo...
Guardado en:
Autores principales: | Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El-Gendy, Maria Castejon, Ali Keshavarzian, Gertjan van Dijk, Sahar El Aidy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Protein intake and the use of levodopa in patients with Parkinson's disease
por: de Moraes Fracasso,Bianca, et al.
Publicado: (2013) -
Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
por: Hirofumi Matsuyama, et al.
Publicado: (2021) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas P, et al.
Publicado: (2013) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: David J Brooks
Publicado: (2008) -
Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: Eva König, et al.
Publicado: (2021)